Desvenlafaxine
- Generic Name
- Desvenlafaxine
- Brand Names
- Pristiq
- Drug Type
- Small Molecule
- Chemical Formula
- C16H25NO2
- CAS Number
- 93413-62-8
- Unique Ingredient Identifier
- NG99554ANW
- Background
Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of venlafaxine. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class. It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).
...
- Indication
Desvenlafaxine is indicated for the treatment of major depressive disorder in adults. It has also been used off-label to treat hot flashes in menopausal women.
- Associated Conditions
- Hot Flashes, Major Depressive Disorder (MDD)
- Associated Therapies
- -
Neurocognition and Work Productivity in Major Depressive Disorder (MDD)
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 47
- Registration Number
- NCT01468610
- Locations
- 🇨🇦
University of British Columbia, Department of Psychiatry, Vancouver, British Columbia, Canada
Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2012-01-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01443208
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- The Medical Research Network
- Target Recruit Count
- 63
- Registration Number
- NCT01316302
- Locations
- 🇺🇸
The Medical Research Network, LLC, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.